Skip to main content
Top
Published in: Calcified Tissue International 4/2008

01-10-2008

Fracture Healing in Mice Deficient in Plasminogen Activator Inhibitor-1

Authors: Charles H. Rundle, Xiaoguang Wang, Jon E. Wergedal, Subburaman Mohan, K.-H. William Lau

Published in: Calcified Tissue International | Issue 4/2008

Login to get access

Abstract

To evaluate the role of plasminogen activator inhibitor (PAI)-1, a key negative regulator of the plasmin system of extracellular matrix proteases in developmental bone growth and fracture repair, the bone phenotype of male adult PAI-1-deficient mice was determined and femoral fracture healing was compared with that of age- and sex-matched wild-type C57BL/6J control mice. Regarding bone phenotype, the length and size (but not cortical thickness) of the femur of male PAI-1-deficient mice were smaller than those of wild-type controls. Although the total bone mineral content of PAI-1-deficient mice was not significantly different from that of wild-type mice, the total bone area in PAI-1-deficient mice was smaller, leading to an increase in total bone mineral density. With respect to fracture healing, PAI-1-deficient mice developed fracture calluses that were larger and more mineralized than those of wild-type mice but only at 14 days postfracture. These changes were even greater given the smaller size of the normal femur in PAI-1-deficient mice. Surprisingly, the larger fracture callus remodeled rapidly to normal size and mineral content by 21 days postfracture. Examination of fracture histology revealed that these changes were associated with a dramatic increase followed by a rapid remodeling of the fracture callus cartilage. The remodeling of fracture callus cartilage in PAI-1-deficient mice also displayed an abnormal pattern. These findings demonstrate for the first time that PAI-1 (and potentially the plasminogen extracellular matrix protease system) is an important regulator of bone size during developmental growth and plays a regulatory role in the determination of fracture callus size, cartilage formation, and resorption during bone fracture repair.
Literature
1.
go back to reference Romer J, Lund LR, Eriksen J, Ralfkiaer E, Zeheb R, Gelehrter TD, Dano K, Kristensen P (1991) Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 97:803–811PubMedCrossRef Romer J, Lund LR, Eriksen J, Ralfkiaer E, Zeheb R, Gelehrter TD, Dano K, Kristensen P (1991) Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 97:803–811PubMedCrossRef
2.
go back to reference Chan JC, Duszcczyszyn DA, Castellino FJ, Ploplis VA (2001) Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 159:1681–1688PubMed Chan JC, Duszcczyszyn DA, Castellino FJ, Ploplis VA (2001) Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 159:1681–1688PubMed
3.
go back to reference Koh TJ, Bryer SC, Pucci AM, Sisson TH (2005) Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration. Am J Physiol Cell Physiol 289:217–223CrossRef Koh TJ, Bryer SC, Pucci AM, Sisson TH (2005) Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration. Am J Physiol Cell Physiol 289:217–223CrossRef
4.
go back to reference Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ (2003) How vitronectin binds to PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10:541–544PubMedCrossRef Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ (2003) How vitronectin binds to PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10:541–544PubMedCrossRef
5.
go back to reference Lazar MH, Christensen PJ, Du M, Yu B, Subbotina NM, Hanson KE, Hansen JM, White ES, Simon RH, Sisson TH (2004) Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol 31:672–678PubMedCrossRef Lazar MH, Christensen PJ, Du M, Yu B, Subbotina NM, Hanson KE, Hansen JM, White ES, Simon RH, Sisson TH (2004) Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol 31:672–678PubMedCrossRef
6.
go back to reference Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD (1997) Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and transfer study in mice. Circulation 96:3180–3191PubMed Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD (1997) Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and transfer study in mice. Circulation 96:3180–3191PubMed
7.
go back to reference Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson F, Collen D, Mulligan RC (1993) Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92:2746–2755PubMedCrossRef Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson F, Collen D, Mulligan RC (1993) Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92:2746–2755PubMedCrossRef
8.
go back to reference Wergedal JE, Sheng MH, Ackert-Bicknell CL, Beamer WG, Baylink DJ (2005) Genetic variation in femur extrinsic strength in 29 different inbred strains of mice is dependent on variations in femur cross-sectional geometry and bone density. Bone 36:111–122PubMedCrossRef Wergedal JE, Sheng MH, Ackert-Bicknell CL, Beamer WG, Baylink DJ (2005) Genetic variation in femur extrinsic strength in 29 different inbred strains of mice is dependent on variations in femur cross-sectional geometry and bone density. Bone 36:111–122PubMedCrossRef
9.
go back to reference Bonnarens F, Einhorn TA (1984) Production of a standard closed fracture in laboratory animal bone. J Orthop Res 2:97–101PubMedCrossRef Bonnarens F, Einhorn TA (1984) Production of a standard closed fracture in laboratory animal bone. J Orthop Res 2:97–101PubMedCrossRef
10.
go back to reference Bancroft JD (2002) Enzyme histochemistry and its diagnostic applications. In: Bancroft JD, Gamble M (eds) Theory and practice of histological techniques. Harcourt, New York, pp 593–620 Bancroft JD (2002) Enzyme histochemistry and its diagnostic applications. In: Bancroft JD, Gamble M (eds) Theory and practice of histological techniques. Harcourt, New York, pp 593–620
11.
go back to reference Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92:2756–2760PubMedCrossRef Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92:2756–2760PubMedCrossRef
12.
go back to reference Daci E, Verstuyf A, Moermans K, Bouillon R, Carmeliet G (2000) Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. J Bone Miner Res 8:1510–1516CrossRef Daci E, Verstuyf A, Moermans K, Bouillon R, Carmeliet G (2000) Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. J Bone Miner Res 8:1510–1516CrossRef
13.
go back to reference Nordstrom SM, Carleton SM, Carson WL, Eren M, Phillips CL, Vaughan DE (2007) Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization. Bone 41:995–1004PubMedCrossRef Nordstrom SM, Carleton SM, Carson WL, Eren M, Phillips CL, Vaughan DE (2007) Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization. Bone 41:995–1004PubMedCrossRef
14.
go back to reference Daci E, Everts V, Torrekens S, van Herck E, Tigchelaar-Gutterr W, Bouillon R, Carmeliet G (2003) Increased bone formation in mice lacking plasminogen activators. J Bone Miner Res 18:1167–1176PubMedCrossRef Daci E, Everts V, Torrekens S, van Herck E, Tigchelaar-Gutterr W, Bouillon R, Carmeliet G (2003) Increased bone formation in mice lacking plasminogen activators. J Bone Miner Res 18:1167–1176PubMedCrossRef
15.
go back to reference Pedrozo HA, Schwartz Z, Robinson M, Gomez R, Dean DD, Bonewald LF, Boyan BD (1999) Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-β1 from the extracellular matrix of growth plate chondrocytes. Endocrinol 140:5806–5816CrossRef Pedrozo HA, Schwartz Z, Robinson M, Gomez R, Dean DD, Bonewald LF, Boyan BD (1999) Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-β1 from the extracellular matrix of growth plate chondrocytes. Endocrinol 140:5806–5816CrossRef
16.
go back to reference Saksela O, Moscatelli D, Sommer A, Rifkin DB (1988) Endothelial cell–derived heparin sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107:743–751PubMedCrossRef Saksela O, Moscatelli D, Sommer A, Rifkin DB (1988) Endothelial cell–derived heparin sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107:743–751PubMedCrossRef
17.
go back to reference Campbell PG, Novak JF, Yanosick TB, McMaster JH (1992) Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130:1401–1412PubMedCrossRef Campbell PG, Novak JF, Yanosick TB, McMaster JH (1992) Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130:1401–1412PubMedCrossRef
18.
go back to reference Lalou C, Silve C, Rosato R, Segovia B, Binoux M (1994) Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology 135:2318–2326PubMedCrossRef Lalou C, Silve C, Rosato R, Segovia B, Binoux M (1994) Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology 135:2318–2326PubMedCrossRef
19.
go back to reference Hughes DE, Salter DM, Dedhar S, Simpson R (1993) Integrin expression in human bone. J Bone Miner Res 8:527–533PubMed Hughes DE, Salter DM, Dedhar S, Simpson R (1993) Integrin expression in human bone. J Bone Miner Res 8:527–533PubMed
20.
go back to reference Daci E, Udagawa N, Martin TJ, Bouillon R, Carmeliet G (1999) The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res 14:946–952PubMedCrossRef Daci E, Udagawa N, Martin TJ, Bouillon R, Carmeliet G (1999) The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res 14:946–952PubMedCrossRef
22.
go back to reference Colnot C, Thompson Z, Miclau T, Werb Z, Helms JA (2003) Altered fracture repair in the absence of MMP9. Development 130:4123–4133PubMedCrossRef Colnot C, Thompson Z, Miclau T, Werb Z, Helms JA (2003) Altered fracture repair in the absence of MMP9. Development 130:4123–4133PubMedCrossRef
23.
go back to reference Tumber A, Papaioannou S, Breckon J, Meikle MC, Reynolds JJ, Hill PA (2003) The effects of serine protease inhibitors on bone resorption in vitro. J Endocrinol 178:437–447PubMedCrossRef Tumber A, Papaioannou S, Breckon J, Meikle MC, Reynolds JJ, Hill PA (2003) The effects of serine protease inhibitors on bone resorption in vitro. J Endocrinol 178:437–447PubMedCrossRef
24.
go back to reference Leloup G, Lemoine P, Carmeliet P, Vaes G (1996) Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor. J Bone Miner Res 11:1146–1157PubMedCrossRef Leloup G, Lemoine P, Carmeliet P, Vaes G (1996) Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor. J Bone Miner Res 11:1146–1157PubMedCrossRef
25.
go back to reference Furlan F, Galbiati C, Jorgensen NR, Jensen J-EB, Mrak E, Rubinacci A, Talotta F, Verde P, Blasi F (2007) Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J Bone Miner Res 22:1387–1396PubMedCrossRef Furlan F, Galbiati C, Jorgensen NR, Jensen J-EB, Mrak E, Rubinacci A, Talotta F, Verde P, Blasi F (2007) Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J Bone Miner Res 22:1387–1396PubMedCrossRef
Metadata
Title
Fracture Healing in Mice Deficient in Plasminogen Activator Inhibitor-1
Authors
Charles H. Rundle
Xiaoguang Wang
Jon E. Wergedal
Subburaman Mohan
K.-H. William Lau
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 4/2008
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-008-9169-7

Other articles of this Issue 4/2008

Calcified Tissue International 4/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine